Format

Send to

Choose Destination
Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14.

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

Author information

1
Department of Oncology, Kantonsspital Graub√ľnden, Loestrasse 170, 7000, Chur, Switzerland. Electronic address: ioannis.metaxas@ksgr.ch.
2
Department of Oncology, Kantonsspital Graub√ľnden, Loestrasse 170, 7000, Chur, Switzerland.

Abstract

Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein we report two patient cases with mesothelioma who received second-line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin. The combination showed promising activity in both cases with manageable toxicity. We discuss the results of this regime in the light of historical as well as emerging data in mesothelioma.

KEYWORDS:

Lurbinectedin; Mesothelioma; Palliative chemotherapy

PMID:
27440191
DOI:
10.1016/j.lungcan.2016.07.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center